These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 698913)

  • 121. A human IgA-myeloma protein with anti-streptococcal hyaluronidase (ASH) activity.
    Videbaek A; Mansa B; Kjems E
    Scand J Haematol; 1973; 10(3):181-5. PubMed ID: 4203485
    [No Abstract]   [Full Text] [Related]  

  • 122. Peptichemio in pretreated patients with plasmacell neoplasms.
    Paccagnella A; Salvagno L; Chiarion-Sileni V; Bolzonella S; De Besi P; Frizzarin M; Pappagallo GL; Fosser VP; Fornasiero A; Segati R
    Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1053-8. PubMed ID: 3780812
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Phase I evaluation of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) and dianhydrogalactitol (DAG; NSC-132313) in patients with advanced neoplastic diseases.
    Creagan ET; Eagan RT; Rubin J
    Med Pediatr Oncol; 1979; 7(2):179-80. PubMed ID: 502975
    [No Abstract]   [Full Text] [Related]  

  • 124. Therapy of myeloma.
    Case DC
    Blood; 1980 Jun; 55(6):1070-1. PubMed ID: 7378579
    [No Abstract]   [Full Text] [Related]  

  • 125. IgE multiple myeloma: a report of the third case.
    Fishkin BG; Orloff N; Scaduto LE; Borucki DT; Spiegelberg HL
    Blood; 1972 Mar; 39(3):361-7. PubMed ID: 4621803
    [No Abstract]   [Full Text] [Related]  

  • 126. Multiple myeloma with renal failure. A case for intensive treatment.
    Harris DC; Ibels LS; Ravich RB; Isbister JP; Wells JV
    Aust N Z J Med; 1983 Apr; 13(2):163-7. PubMed ID: 6577835
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Vindesine in plasma cell tumors.
    Salvagno L; Paccagnella A; Chiarion Sileni V; De Besi P; Frizzarin M; Casara D; Fiorentino MV
    Tumori; 1985 Dec; 71(6):533-6. PubMed ID: 4082286
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Cyclic oscillation of blood neutrophils in a patient with multiple myeloma.
    Chikkappa G; Chanana AD; Chandra P; Cronkite EP; Thompson KH
    Blood; 1980 Jan; 55(1):61-6. PubMed ID: 6965349
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Clinical evaluation of Asaley.
    Bodey GP; Gottlieb JA; Burgess MA; Alexanian R
    Med Pediatr Oncol; 1977; 3(4):365-71. PubMed ID: 927333
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Optic neuroretinitis in association with BCNU and procarbazine therapy.
    Lennan RM; Taylor HR
    Med Pediatr Oncol; 1978; 4(1):43-8. PubMed ID: 625262
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Emotional support for the multiple myeloma patient.
    Rickel L
    Nursing; 1976 Apr; 6(4):76-80. PubMed ID: 1045032
    [No Abstract]   [Full Text] [Related]  

  • 132. Normal pregnancy in multiple myeloma treated with cyclophosphamide.
    Lergier JE; Jiménez E; Maldonado N; Veray F
    Cancer; 1974 Oct; 34(4):1018-22. PubMed ID: 4417641
    [No Abstract]   [Full Text] [Related]  

  • 133. Timed sequential chemotherapy of cytoxan-refractory multiple myeloma with cytoxan and adriamycin based on induced tumor proliferation.
    Karp JE; Humphrey RL; Burke PJ
    Blood; 1981 Mar; 57(3):468-75. PubMed ID: 7006709
    [TBL] [Abstract][Full Text] [Related]  

  • 134. The growth fraction of human myeloma cells.
    Drewinko B; Alexanian R; Boyer H; Barlogie B; Rubinow SI
    Blood; 1981 Feb; 57(2):333-8. PubMed ID: 7448427
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Prednisone treatment of myeloma.
    Salmon SE
    Blood; 1984 Apr; 63(4):970. PubMed ID: 6704547
    [No Abstract]   [Full Text] [Related]  

  • 136. Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.
    Brugnatelli S; Riccardi A; Ucci G; Mora O; Barbarano L; Piva N; Piccinini L; Bergonzi C; De Paoli A; Di Stasi M; Rinaldi E; Trotti G; Petrini M; Ascari E
    Br J Cancer; 1996 Mar; 73(6):794-7. PubMed ID: 8611382
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Sensitization of human melanoma cells to melphalan cytotoxicity by adriamycin and carmustine.
    Jevtović-Todorović V; Guenthner TM
    J Cancer Res Clin Oncol; 1991; 117(4):313-20. PubMed ID: 2066351
    [TBL] [Abstract][Full Text] [Related]  

  • 138. Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma.
    Presant CA; Klahr C
    Cancer; 1978 Sep; 42(3):1222-7. PubMed ID: 698913
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
    Case DC; Lee DJ; Clarkson BD
    Am J Med; 1977 Dec; 63(6):897-903. PubMed ID: 605911
    [No Abstract]   [Full Text] [Related]  

  • 140. Combination therapy for multiple myeloma.
    Alexanian R; Salmon S; Bonnet J; Gehan E; Haut A; Weick J
    Cancer; 1977 Dec; 40(6):2765-71. PubMed ID: 589554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.